Federated Hermes, Inc. Oncternal Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.86 - $22.2 $114 - $2,952	-133 Reduced 9.29%	1,298 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.83 - $17.8 $646 - $13,866	779 Added 119.48%	1,431 $1,000
Q2 2022 Aug 15, 2022	BUY	$0.7 - $1.56 $131 - $293	188 Added 40.52%	652 $1,000
Q1 2022 May 13, 2022	BUY	$1.37 - $2.43 $635 - $1,127	464 New	464 $1,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $62.7M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.